ASCO Conference Coverage

Joint ASCO/CCO guidelines for advanced prostate cancer issued

Recommendations are for men whose tumors have grown resistant to hormonal therapies were issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) in Canada.

ASCO: Family doctors can improve mammogram return rates

Women overdue for mammogram respond better to postcard plus reminder letter from family physician.

ASCO: Angelina Jolie announcement responsible for BRCA1/2 testing boost

Celebrity story helped double rates of genetic testing in following six months at one cancer center.

ASCO: Risks greater for double mastectomy

Women with breast cancer who have a double mastectomy are at higher risk of certain complications than those who have a single mastectomy, though the overall complication rate associated with breast cancer surgery is small.

New way to predict response to chemotherapy in triple-negative breast cancer

The presence of tumor-infiltrating lymphocytes ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer, according to a new study.

ASCO guidelines recommend adjuvant endocrine therapy extension

The American Society of Clinical Oncology (ASCO) is updating its guidelines on adjuvant endocrine therapy to recommend tamoxifen for up to 10 years for women with nonmetastatic hormone receptor-positive breast cancer.

Early impressions and comments from ASCO thought leaders

The 2014 ASCO Annual Meeting tweeters share their opinions on oncology care, and more. Here is a selection of their thoughts as expressed via social media.

ASCO: Unneeded cancer care is rare

New study challenges belief that inappropriate cancer treatments fuel health care costs, researcher says.

ASCO: LDCT lung cancer screening model will up diagnoses

Implementation of the U.S. Preventive Services Task Force recommendations for low-dose computed tomography (LDCT) lung cancer screening is expected to increase lung cancer diagnoses and increase Medicare expenditure.

ASCO releases advanced HER2+ breast cancer guidelines

The American Society for Clinical Oncology (ASCO) has issued recommendations for the treatment of HER2-positive advanced breast cancer and advanced HER2-positive breast cancer with brain metastases.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs